Compare Johnson & Johnson (JNJ) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Lockheed Martin Corporation — how do they compare? Johnson & Johnson trades at $261.04 (market cap $618.09B), while Lockheed Martin Corporation trades at $508.2 (market cap $117.22B). The key difference: Johnson & Johnson is far larger — about 5.3× Lockheed Martin Corporation's market cap, and Lockheed Martin Corporation pays the higher dividend (2.72%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Lockheed Martin Corporation for 86 Days on average.
| JNJ | LMT | |
|---|---|---|
Market Cap | $618.09B | $117.22B |
Volume | 6,050,983 | 1,101,121 |
Sector | Health | Industrials |
52-Week High | $278.43 | $676.70 |
52-Week Low | $186.00 | $439.19 |
Typical Hold Time | 129 Days | 86 Days |
Enterprise Value | $646.37B | $133.96B |
Dividend Yield | 2.09% | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Lockheed Martin (LMT) trades at $499.22, down 2.14% over the past day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 18.73 and net income margin of 8.16%, though recent quarters saw mixed earnings results. Revenue growth is steady, reaching $75.05B in 2025, and the company maintains a robust dividend history, recently declaring a $3.45 payout. Analyst consensus remains bullish with a $635.33 price target, supported by ongoing defense spending and strategic initiatives like AI integration and Skunk Works innovation.
Outlook for LMT is positive due to solid defense contracts and technological advancements, but risks include fixed-price contract volatility and competitive pressures. The stock offers value with a below-sector P/E and high institutional confidence, though investors should monitor execution on earnings targets and macroeconomic impacts on defense budgets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
